Abdulmunaim Eid
Neurology · Saint Louis, MONPI 1346739638
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 200 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,121 and has fallen 95.7% since, to $48 in 2024.
Across 200 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$527
- CSL Behring$475
- Johnson & Johnson$362
- Neurocrine Biosciences, Inc.$360
- Genentech USA, Inc.$327
- Amgen$296
- plus $1K from 20 others
What the payments were for
- Speaking & faculty fees$431%
- Food & beverage$3,65199%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 29 | $527 |
| CSL Behring | 22 | $475 |
| Johnson & Johnson | 20 | $362 |
| Neurocrine Biosciences, Inc. | 18 | $360 |
| Genentech USA, Inc. | 19 | $327 |
| Amgen | 16 | $296 |
| AstraZeneca(2 entities) | 16 | $256 |
| Eisai Inc. | 14 | $232 |
| Sanofi-aventis U.S. LLC | 6 | $125 |
| Biogen | 5 | $78 |
| AbbVie(2 entities) | 4 | $73 |
| Novartis | 3 | $67 |
| Akcea Therapeutics, Inc. | 3 | $63 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $61 |
| Saol Therapeutics Inc. | 4 | $61 |
| Avanir Pharmaceuticals, Inc. | 3 | $52 |
| Acorda Therapeutics, Inc | 2 | $43 |
| Tanabe Pharma America, Inc. | 3 | $42 |
| Argenx US, Inc. | 1 | $33 |
| GRT US Holding, Inc. | 1 | $29 |
| Merz Pharmaceuticals, LLC | 1 | $27 |
| Pfizer | 2 | $26 |
| Catalyst Pharmaceuticals, Inc. | 2 | $26 |
| Shire North American Group Inc | 1 | $21 |
| Merz North America, Inc. | 1 | $16 |
| Chiesi USA, Inc. | 1 | $16 |
How this compares
$3,694 in reported general payments places this provider in the 65th percentile of 381 neurology providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 13 | $560 |
Paid to pharmacies, not to this prescriber.
Other neurology in Saint Louis
- Barry SingerSaint Louis$1.9M
- Mark TullmanSaint Louis$1.5M
- Robert NaismithSaint Louis$677K
- Arun VaradhacharySaint Louis$273K
- Anne CrossSaint Louis$190K
- David HoltzmanSaint Louis$165K
- Ghazala HayatSaint Louis$155K
- Pratap ChandSaint Louis$139K
- Lee TempelSaint Louis$121K
- Salim ChahinSaint Louis$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.